Survival of grade 1 endometrial Ca is excellent, no matter how you treat it


Different treatment of grade 1 endometrial cancer seems to have no effect on the survival rate.

Endrocrine-disrupting chemicals (EDCs-natural or synthetic compounds that interfere with hormone biosynthesis or metabolism and alter homeostatic control or reproduction-are a significant concern to public health, according to the first scientific statement on the subject issued by the Endocrine Society.

Representing a broad class of molecules, such as organochlorinated pesticides and industrial chemicals, plastics and plasticizers, fuels, and many other chemicals present in the environment and in widespread use, EDCs have wide-ranging effects on male and female reproduction, breast development and cancer, prostate cancer, neuroendocrinology, thyroid function, metabolism and obesity, and cardiovascular endocrinology. Pathways of disruption involve, but are not limited to, estrogenic, antiandrogenic, thyroid, peroxisome proliferator-activated receptor γ, retinoid, and actions through other nuclear receptors; steroidogenic enzymes; and neurotransmitter receptors and systems.

The statement explains that the most important determinants of endocrine disruption are age at exposure; the time between exposure and the manifestation of a disorder; the mixture of chemicals to which an individual is exposed; nontraditional dose-response dynamics (e.g., that sometimes low doses exert more potent effects than higher doses); and long-term latent effects (e.g., affecting subsequent generations).

Diamanti-Kandarakis E, Bourguignon JP, Guidice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009;30:293-342.

Related Videos
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.